Find the Perfect Plan for Your Investment Journey
Latest price
52 Week Range
$0.26 - $3.63
Next Earnings Date
May 08 2025
Next Earnings Date
May 08 2025
Latest price
Market Cap | $48.61M |
EV | $-57.36M |
Shares Outstanding | 124.63M |
Beta | 1.66 |
Analyst Rating | BUY |
Analyst Target Price | $4.71 |
P/E 2025E | - |
P/Revenue 2025E | 1.76x |
Revenue | 880.20% |
EPS | 38.50% |
Operating Cash Flow | 16.20% |
Free Cash Flow | 16.30% |
Revenue | -19.60% |
EPS | -14.90% |
Operating Cash Flow | -8.80% |
Free Cash Flow | -2.80% |
Gross Margin 2025E | 100.00% |
Net Profit Margin 2025E | -356.58% |
ROE 2025E | -68.90% |
ROCE 2024 | -505.14% |
DPS 2025E | $0.00 |
Payout Ratio 2025E | 0.00% |
Div. Yield 2025E | 0.00% |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Mersana Therapeutics, Inc.
MRSN
Sector
Healthcare
Industry
Biotechnology
CEO
Huber, Martin
Employees
102
Website
www.mersana.comIPO Date
2017-06-28
Headquarters
840 Memorial Drive, Cambridge, Massachusetts, 02139, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved